XIAP: A Promising Target for HBV Treatment & Biomarker (G331)

Target Name: XIAP

NCBI ID: G331

XIAP

XIAP: A Promising Target for HBV Treatment & Biomarker

Hepatitis B virus (HBV) is a highly infectious and potentially fatal disease that affects millions of people worldwide. The virus causes chronic inflammation in the liver, leading to liver damage and the development of various health complications. One of the most common treatments for HBV is a drug called XiAP (hIAP-3), which is currently being studied as a potential drug target or biomarker.

XIAP (hIAP-3) is a small protein that is found in the blood of individuals with HBV. It is made by the liver and has been shown to play a role in the replication of the virus. By blocking the activity of the protein, XiAP has been shown to be effective in reducing the amount of virus that is present in the blood.

XIAP is a potential drug target because it is involved in the replication of the virus and has been shown to be effective in reducing the amount of virus that is present in the blood. This suggests that it could be a useful target for a treatment for HBV.

Currently, there are several studies that are being conducted to determine the effectiveness of XiAP as a drug. These studies are looking at the effects of XiAP on the replication of HBV in both infected individuals and those who have already developed the disease.

One of the most promising studies is a trial that is being conducted at the University of California, San Diego. In this trial, researchers are using XiAP to treat HBV-positive individuals who have not responded to other treatments. The researchers are looking to see if XiAP is effective in reducing the amount of virus that is present in the blood and improving the overall health of the individuals.

Another promising study is a trial that is being conducted at the National Institute of Allergy and Infectious Diseases (NIAID). In this trial, researchers are using XiAP to treat HBV-positive individuals who have not responded to other treatments. The researchers are looking to see if XiAP is effective in reducing the amount of virus that is present in the blood and improving the overall health of the individuals.

XIAP is also being studied as a potential biomarker for HBV. By measuring the level of XiAP in the blood, researchers can determine the level of the virus and track its replication over time. This can be an important tool for researchers to understand how the virus is transmitted and how it affects the body.

Conclusion

XIAP (hIAP-3) is a small protein that is found in the blood of individuals with HBV. It is made by the liver and has been shown to play a role in the replication of the virus. By blocking the activity of the protein, XiAP has been shown to be effective in reducing the amount of virus that is present in the blood. This suggests that it could be a useful target for a treatment for HBV.

Currently, there are several studies that are being conducted to determine the effectiveness of XiAP as a drug. These studies are looking at the effects of XiAP on the replication of HBV in both infected individuals and those who have already developed the disease.

XIAP is also being studied as a potential biomarker for HBV. By measuring the level of XiAP in the blood, researchers can determine the level of the virus and track its replication over time. This can be an important tool for researchers to understand how the virus is transmitted and how it affects the body.

Overall, XiAP is a promising protein that is being studied as a potential drug target and biomarker for HBV. Further research is needed to determine its effectiveness and to develop safe and effective treatments for this disease.

Protein Name: X-linked Inhibitor Of Apoptosis

Functions: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. Acts as a direct caspase inhibitor (PubMed:11257230, PubMed:11257231, PubMed:12620238). Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry (PubMed:11257230, PubMed:11257231, PubMed:16352606, PubMed:16916640). Inactivates CASP9 by keeping it in a monomeric, inactive state (PubMed:12620238). Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitination of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitination of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinating COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Ubiquitinates and therefore mediates the proteosomal degradation of BCL2 in response to apoptosis (PubMed:29020630). Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nod-like receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program

The "XIAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XIAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets